Momentum Is Back At Cipla In Q2
However, The Indian Firm Has Seen Albuterol Delayed In US
Cipla had a strong run across key businesses in Q2, with products like generic Sensipar retaining share in the US despite stiff competition. But launch timelines for generic albuterol in the US have been pushed back to fiscal 2021.